07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Cytox sales and marketing update

Cytox launched its variaTECT SNP array genetic biomarker test and SNPfitR analysis software ito diagnose Alzheimer’s disease by determining amyloid positive patients from blood or archived samples. Cytox said Affymetrix Inc. will begin formal product...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Affymetrix, Enzo microarrays news

Affymetrix paid Enzo $10 million to settle a patent infringement suit regarding Enzo’s U.S. Patent No. 7,064,197, covering a nucleic acid array, system and non-porous solid. Enzo filed the suit in 2012 in the U.S....
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Affymetrix, Cytox deal

Cytox and Affymetrix partnered to develop and commercialize a blood-based genetic assay for Alzheimer’s disease (AD) and mild cognitive impairment (MCI). The collaboration will combine Affymetrix’s Axiom genotyping platform with a customized genetic variation panel...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Affymetrix, MTI deal

Affymetrix and MTI’s EverGene Ltd. subsidiary partnered for genetic research and personal genomics services in Japan. Affymetrix is supplying to EverGene custom genotyping arrays based on its Axiom Genotyping Solution for the companies’ research program...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Affymetrix, U.K. Biobank Ltd. sales and marketing update

Affymetrix will use its Axiom Genotyping Solution to genotype 500,000 DNA samples donated by U.K. residents. The data will be used by U.K. Biobank and researchers to gain insight into genetic factors underlying disease for...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Affymetrix, Centre for Proteomic and Genomic Research deal

Affymetrix will supply not-for-profit CRO Centre for Proteomic and Genomic Research (CPGR) with the company's GeneTitan Multi-Channel Instrument and Axiom Genotyping Arrays. The CRO will use the products to provide gene expression and genotyping services...
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

Axiom Molecular Pty. Ltd., University of Queensland deal

UniQuest Pty. Ltd., the commercialization arm of the university, partnered with Axiom to develop and commercialize PET radiopharmaceuticals for diagnosing cancer and brain disorders. Axiom will enhance facilities at the university's Center for Advanced Imaging...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Affymetrix sales and marketing update

Affymetrix launched its Axiom Exome Genotyping Arrays worldwide to screen for putative functional SNPs, insertions/deletion mutations and other variants in exons. The panel of markers is derived from variants discovered from sequencing 12,000 ethnically diverse...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Company News

Affymetrix sales and marketing update

Affymetrix launched 18 Affymetrix Gene 1.1 ST Array Strips worldwide for whole-transcript resolution gene expression analysis for research use only. Separately, the company launched its Axiom Genome-Wide Pan-African Array worldwide for population-optimized genotyping. The plate...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

TAK-442: Development discontinued

Takeda discontinued development of TAK-442 based in part on its full analysis of the 3-stage, double-blind, international Phase II AXIOM-ACS trial in 2,753 patients with ACS. The trial showed that there were no significant differences...